- Confidently report all four mutation classes – SNVs, indels, fusions, and CNVs—from just 10 – 50 ng of cfDNA.
- Delivers exceptional analytical performance supported by integrated digital error suppression (iDES) strategies, combining molecular barcodes with in silico error suppression techniques.2,3
- Analyze plasma containing DNA from a variety of solid tumor types using a single workflow optimized for running up to 16 samples at a time.
- Rely on a single trusted supplier for complete support of your isolations, library prep, target enrichment panels, and post-hybridization reagents.
- Receive an inclusive solution with the required reagents, a robust bioinformatics pipeline, and software for analysis and reporting to keep your lab at the forefront of cancer research.†
- Lung, Colorectal, Breast, Gastric, Prostate, Glioma, Melanoma, Ovarian, Thyroid, and Pancreatic
- Non-invasive tumor profiling
- Non-invasive detection of resistance biomarkers
- Investigation of emerging cancer biomarkers
1. National Comprehensive Cancer Network. http://www.nccn.org. October 15, 2016. 2. Newman AM, Lovejoy AF, Klass DM, et al. Integrated digital error suppression for improved detection of circulating tumor DNA. Nature Biotechnology. 2016;34(5):547–555. doi:10.1038/nbt.3520. 3. Newman AM, Bratman SV, To J, et al. An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nature Medicine. 2014;20(5):548–554. doi:10.1038/nm.3519. † Required hardware: Illumina NextSeq 500/550 sequencer and Roche Oncology Analysis Server. NextSeq 500/550 instruments and associated sequencing reagents are manufactured and sold by lllumina and are not supplied by Roche
For Research Use Only. Not for use in diagnostic procedures.
AVENIO is a trademark of Roche. NEXTSEQ is a trademark of Illumina. All other product names and trademarks are the property of their respective owners.
© 2020 Roche Sequencing & Life Science. All rights reserved.